Total
0
Shares
Nuheara (ASX:NUH) - CEO, Justin Miller
CEO, Justin Miller
Source: Nuheara
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Nuheara (NUH) completes recruitment for its clinical trial to support its expansion into regulatory-approved hearing aids
  • More than 50 per cent of the candidates have begun the trial, with the remaining expected to begin within the next week
  • The company says it remains on target to submit its FDA 510(K) submission in the first quarter of 2022 
  • Nuheara remained steady today at 1.9 cents per share

Nuheara (NUH) has completed recruitment for its clinical trial to support its expansion into regulatory-approved hearing aids.     

More than 50 per cent of its candidates have now begun the trial, with the remaining expected to begin within the next week.

Nuheara has also engaged NAMSA, the world’s only solely medical device-focused contract research organisation and medical device biocompatibility laboratory, to conduct cytotoxicity, irritation and sensitisation testing.

The testing is hoped to demonstrate biocompatibility of Nuheara’s proposed hearing aid devices.

Previous cytotoxicity testing was found to meet requirements and sensitisation testing showed no evidence of contact sensitisation.

Managing Director and CEO Justin Miller said the company is pleased with the progress it’s been making with its clinical trial and successful completion of the biocompatibility testing.

“These are important milestones on our planned path to FDA 510(K) submission, which remains on target for the first quarter of 2022,” said Justin Miller.

“With regulatory changes being implemented to the hearing sector in the US, we have a company defining and vast opportunity to expand into medical devices in advance of future over the counter (OTC) hearing aid products and sales in the US.

“The proposed and pending FDA OTC regulations are expected to be enacted in late 2022, and the work we are doing now to support regulatory approved hearing aids will allow Nuheara to reach and service the approximately 38 million American adults who report some level of hearing difficulty,.”

Nuheara remained steady today at 1.9 cents per share.

NUH by the numbers
More From The Market Herald
Vimy Resources (ASX:VMY) - Interim CEO, Steven Michael

" Vimy Resources (ASX:VMY) advances controversial Mulga Rock Uranium Project

Vimy Resources (VMY) has submitted a notification of ‘substantial commencement’ for the Mulga Rock Uranium Project in Western Australia.

" Dynamic Group (ASX:DDB) secures six short term contracts worth up to $14.1m

Dynamic Group (DDB) has secured six short-term contracts through its wholly-owned subsidiaries, Orlando Drilling and Drill & Blast.

" Horseshoe Metals (ASX:HOR) completes ASX requirements for potential relisting

Horseshoe Metals (HOR) has completed the activity requirements for the ASX to consider lifting its suspension from trading.
Bardoc Gold (ASX:BDC) - CEO, Robert Ryan

" Bardoc Gold (ASX:BDC) confirms extensions of Zoroastrian deposit

Bardoc Gold (BDC) has announced most recent assay results from the Zoroastrian deposit within its namesake project “exceeded expectations”.